Citations |
Bioorg Med Chem. 2019 Sep 1;27(17):3836-3845. <br>Clin Drug Investig. 2019 Mar;39(3):285-299. <br>J Infect Dis. 2022 Sep 19;jiac386.<br>J Mol Biol. 2022 Feb 22;167507.<br>J Neuroimmune Pharmacol. 2017 Dec;12(4):682-692.<br>J Virol. 2017 Jan 18;91(3). pii: e02152-16.<br>Life Sci. 9 September 2022, 120948.<br>Molecules. 2022 Dec 12;27(24):8829.<br>PeerJ Physical Chemistry. 2019, 1:e6.<br>Pharmaceuticals. 2023 Aug 8, 16(8), 1118.<br>Phytomedicine. 2016 Nov 15;23(12):1383-1391. <br>Preprints. 2024 Apr 23.<br>Preprints. 2024 Feb 19.<br>SSRN. 2023 Mar 30.<br>Virol Sin. 2023 May 10;S1995-820X(23)00054-8.<br>Virology. 2023 Jun 21.<br>Viruses. 2021 Jan 18;13(1):E131.<br>Plant Biosyst. 2018, 1-8.<br>PLoS One. 2018 Mar 30;13(3):e0195168.<br>[1]Moss DM, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012 Jun;56(6):3020-6<br>[2]Xu P, et al. Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell Proliferation In Vivo and In Vitro. J Neuroimmune Pharmacol. 2017 Dec;12(4):682-692.<br>[3]Hare S, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011 Oct;80(4):565-72.<br>[4]Lewis, M.G., et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology, 2010. 7: p. 21.<br>[5]Hicks C, et al. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009 Apr 1;48(7):931-9<br>[6]Hare, S., et al., Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A, 2010. 107(46): p. 20057-62. |